Description
,An agonist of nociceptin-, µ-, ĸ-, and δ-opioid receptors (Kis = 0.9, 0.7, 2.6, and 18 nM, respectively); >100-fold selective for these receptors over a panel of more than 100 ion channels, neurotransmitter transporters, receptors, and enzymes, but does bind to the 5-HT5A receptor (Ki = 8.7 nM); inhibits nociceptin-, DAMGO-, and SNC 80-induced GTPɣS binding in CHO cells expressing nociceptin-, µ-, and δ-opioid receptors, respectively (EC50s = 13, 1.2, and 110 nM, respectively), as well as U69,593-induced GTPɣS binding in HEK293 cells expressing the ĸ-opioid receptor (EC50 = 17 nM); increases the paw withdrawal threshold in rat models of bone cancer pain and streptozotocin-induced diabetic neuropathy (ED50s = 3.6 and 0.5 µg/kg, respectively, i.v.); increases paw weight bearing on the ipsilateral side in a rat model of arthritis induced by complete Freund’s adjuvant (CFA) and M. tuberculosis (ED50 = 5.5 µg/kg, i.v.)
Formal name: (1α,4β)-6′-fluoro-4′,9′-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1′(3′H)-pyrano[3,4-b]indol]-4-amine
Synonyms: GRT6005
Molecular weight: 378.5
CAS: 863513-91-1
Purity: ≥98%
Formulation: A solid
